Nicotine mouthspray
Phase 3Small molecule
Nicotine mouthspray is one of 25 small molecule programs targeting Smoking Cessation. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
34 competitors in Smoking Cessation
#DrugCompanyPhaseTrials
1Nicorette
PfizerApproved
Chantix
PPrism Pharmaceuticals
Approved
Wellbutrin
GGlaxo Dba Glaxosmithkline
Approved
Lunesta
Akero TherapeuticsApproved
Viagra
VViatris Specialty LLC
Approved
Nicotine Free Cigarettes
PfizerPhase 3
Wellbutrin
GSKPhase 3
Belsomra
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Inderal
WWyeth-Lederle Vaccines
Approved
Nicotine Replacement
GSKPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nicotine mouthspray. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details